Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.57 |
| ▸ | CA2 | P00918 | 7/20 | 0.57 |
| ▸ | CA12 | O43570 | 6/20 | 0.57 |
| ▸ | CA9 | Q16790 | 6/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.57 |
| ▸ | CA7 | P43166 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330192 | 0.88 | ABL1 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1505512 | 0.80 | NOTUM (0.46) | CA1CA2CA12CA9CA14 | |
| SCHEMBL21383989 | 0.80 | ABL1 (0.43) | CA1CA2CA12CA9CA14 | |
| SCHEMBL26306813 | 0.77 | ABL1 (0.42) | CA1CA2CA12CA9CA14 | |
| SCHEMBL46504 | 0.73 | CA12 (0.91) | CA1CA2CA12CA9CA14 | |
| Methyl 3,5-Dihydroxybenzoate SCHEMBL38869 | 0.73 | CA1 (1.00) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16319046 | 0.72 | XDH (0.43) | KDM4ELMNAXDHPOLBGAA | |
| SCHEMBL3855521 | 0.71 | LMNA (0.38) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2818943 | 0.70 | ABL1 (0.67) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15654257 | 0.70 | CA1 (0.50) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737161-B2 | Condensed furan compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-06-15 | — | — | US | disclosed |
| US-20090156803-A1 | Condensed furan compounds | KAWAGUCHI TAKAYUKI | 2009-06-18 | — | — | US | disclosed |
| US-7514449-B2 | Fused furan compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | CA1 4414/4885CA2 3163/4885CA12 4228/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | CA1 4325/4885CA2 2450/4885CA12 3684/4885 |
| US-20090156803-A1 | Condensed furan compounds | F2, F12, F11 | CA1 3011/4885CA2 1610/4885CA12 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.